Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiaoping Su

Showing results (141-150 of 199) with videos related to

Pageof 20
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2016
DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell CarcinomasGabriel G Malouf, Xiaoping Su, Jianping Zhang, et al.
Science (New York, N.Y.)|January 28, 2006
Large-scale sequence analysis of avian influenza isolatesJohn C Obenauer, Jackie Denson, Perdeep K Mehta, et al.
ACS Nano|March 21, 2025
Visual Antimicrobial Gold Nanocluster Hydrogel with Inflammation-Responsive and Time-Regulated Swelling/Degradation for Regenerative Endodontic ProceduresBeibei Xie, Chunyun Liang, Cong Liu, et al.
Cancer Research|July 30, 2017
<i>NSD1</i> Inactivation and <i>SETD2</i> Mutation Drive a Convergence toward Loss of Function of H3K36 Writers in Clear Cell Renal Cell CarcinomasXiaoping Su, Jianping Zhang, Roger Mouawad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Molecular characterization of the pediatric preclinical testing panelGeoffrey Neale, Xiaoping Su, Christopher L Morton, et al.
Leukemia|December 19, 2025
BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AMLChristine E Birdwell, Warren Fiskus, Christopher P Mill, et al.
Nature|March 9, 2007
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemiaCharles G Mullighan, Salil Goorha, Ina Radtke, et al.
Blood|October 3, 2021
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2Christopher P Mill, Warren Fiskus, Courtney D DiNardo, et al.
Leukemia|December 12, 2023
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpressionChristine E Birdwell, Warren Fiskus, Tapan M Kadia, et al.
Blood Cancer Journal|January 12, 2022
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)Warren Fiskus, Steffen Boettcher, Naval Daver, et al.
Pageof 20

Showing results (141-150 of 199) with videos related to

Sort By:
Pageof 20
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2016
DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell CarcinomasGabriel G Malouf, Xiaoping Su, Jianping Zhang, et al.
Science (New York, N.Y.)|January 28, 2006
Large-scale sequence analysis of avian influenza isolatesJohn C Obenauer, Jackie Denson, Perdeep K Mehta, et al.
ACS Nano|March 21, 2025
Visual Antimicrobial Gold Nanocluster Hydrogel with Inflammation-Responsive and Time-Regulated Swelling/Degradation for Regenerative Endodontic ProceduresBeibei Xie, Chunyun Liang, Cong Liu, et al.
Cancer Research|July 30, 2017
<i>NSD1</i> Inactivation and <i>SETD2</i> Mutation Drive a Convergence toward Loss of Function of H3K36 Writers in Clear Cell Renal Cell CarcinomasXiaoping Su, Jianping Zhang, Roger Mouawad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Molecular characterization of the pediatric preclinical testing panelGeoffrey Neale, Xiaoping Su, Christopher L Morton, et al.
Leukemia|December 19, 2025
BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AMLChristine E Birdwell, Warren Fiskus, Christopher P Mill, et al.
Nature|March 9, 2007
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemiaCharles G Mullighan, Salil Goorha, Ina Radtke, et al.
Blood|October 3, 2021
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2Christopher P Mill, Warren Fiskus, Courtney D DiNardo, et al.
Leukemia|December 12, 2023
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpressionChristine E Birdwell, Warren Fiskus, Tapan M Kadia, et al.
Blood Cancer Journal|January 12, 2022
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)Warren Fiskus, Steffen Boettcher, Naval Daver, et al.
Pageof 20